Intermountain Healthcare company Navican launches precision cancer care service

Navican, a genomics research and testing company affiliated with Salt Lake City-based Intermountain Healthcare, will roll out a precision cancer care service dubbed TheraMap.

Navican, which Intermountain established in October 2016, uses precision medicine to identify individual mutations within patients' tumors to help oncologists personalize cancer prevention and treatment options. Intermountain launched Navican to provide outside hospitals an opportunity to use sequencing tests developed at the health system.

Navican officials plan to integrate a clinical quality control solution from SeraCare Life Sciences to support the company's genomics workflows. The SeraCare software will track quality control metrics and benchmark the operational performance of TheraMap's next-generation sequencing diagnostics.

The integrated solution will connect SeraCare's next-generation sequencing quality control management software into the Philips IntelliSpace Genomics Platform, which informs precision medicine treatments using large-scale genomic and clinical data analysis.

Royal Philips entered into an agreement to help hospitals access Navican's precision medicine program in June.

"Navican is excited to add SeraCare Life Sciences to the list of industry leaders we've partnered with as we launch our TheraMap precision cancer service," Keith Gligorich, laboratory operations director at Navican, said in an April 17 statement. "We are now able to generate reports and track assay performance from our clinical samples with Philips and standardized reference materials with SeraCare."

More articles on data analytics & precision medicine:
NIH's precision medicine program 'All of Us' to launch in May — 5 things to know
Data analytics segment cinches top funding spot among health IT startups, report finds
Intermountain Healthcare launches long-term Precise study to collect genomic data

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.